Manohar Katakam, PH.D.
Founder & CEO
Experienced biotech/pharma entrepreneur with more than 25 years of experience in developing and marketing a diverse therapeutic area products. Dr. Katakam raised equity and debt capital, and managed operations leading to successful high-valued corporate exit strategies. Major pharmaceutical industry experience included successful tenures at Centocor, Aventis, Wyeth and Pfizer. Dr Katakam co-founded NuTherapeutics to develop and commercialize thin-film dosage forms of prescription products which he guided to a successful exit.
He established the orphan disease product company, Makindus,and led product development to Phase 3 readiness in both the US and in EU. He obtained his bachelor degree in pharmacy from Kakatiya University, and his MS and Ph.D. in Pharmaceutical Sciences from Auburn University.
Arthur Schwartz, PH.D.
Sr VP, Scientific Affairs
Arthur Schwartz is a Professor Emeritus at Microbiology and Immunology, Temple University Medical School. Dr Schwartz’s research focused on cancer chemoprevention and experimental gerontology. Has more than 40 publications on biological effects and mechanism of action of DHEA and structural analogs. Principle investigator and inventor (14 US and foreign patents) in development of non-androgenic DHEA analogs as potential human drugs. Received B.A. (Biology) from Johns Hopkins University, and Ph.D. (Microbiology and Immunology) from Harvard University.
Bo Allen, PH.D.
Senior VP, Regulatory Affairs
Carroll “Bo” Allen has over 40 years experience in multiple leadership positions within the pharmaceutical industry including 20 years in major pharmaceutical companies (Boehringer Ingelheim, Ciba Geigy, Sandoz, and Novartis). He has executive experience in various start-up biopharmaceutical companies including CoCensys, Kimeragen, and IgX. He founded Asklepion Biopharmaceuticals and Versalion Pharmaceuticals. He has extensive experience in the United States and global orphan drug markets and regulations as well as the implementation of orphan drug strategies.
He is experienced in clinical development, business development and marketing activities for orphan products as well as FDA and EMEA regulatory documentation and compliance, planning and implementation including cGMP, GLP and HIPPA practices. Dr. Allen has a Masters in Biologics Sciences from the University of Tennessee Knoxville and a Ph.D. from South Hampton University, UK.
Chief Financial Officer
Dave brings over thirty years of senior financial leadership experience. Most recently he was Chief Financial Officer for ImmunoGen, Inc. an oncology focused biotech based in Waltham, MA. During his tenure at ImmunoGen, he led several public offerings as well as a creative, non-dilutive royalty financing. Prior to ImmunoGen, Dave served as CFO for Aveo Oncology and Genzyme Biosurgery where he lead both of their initial public offerings as well as leading several strategic initiatives, both on the buy-side as well as the sell-side.
Mr. Johnston earned a B.S. at Washington and Lee University and an MBA at the University of Michigan. Mr. Johnston sat on the board of directors of RAW Art Works, a nonprofit youth arts organization, as well as Tissue Banks International, one of the largest eye and tissue bank non-profits in the United States.
W. James Alexander, MD, MPH, FACP, FIDSA
Dr. Alexander is an internist and infectious disease specialist. After obtaining his medical degree at the University of Mississippi, Dr. Alexander completed Internal Medicine training at the University of Alabama at Birmingham and a Fellowship in Infectious Diseases. After a decade as a Public Health Officer, Dr. Alexander joined the pharma industry and supervised US clinical development of antibacterials and antivirals at Beecham Laboratories. Dr. Alexander joined Glaxo in 1990 and played a key role in US Phase 3 clinical studies for the treatment of asthma. Subsequently, Glaxo chose Dr. Alexander as the international clinical leader for lamivudine as a treatment for HIV infection.
Dr. Alexander’s expertise was next recognized by his appointment as head of Glaxo (US) Pharmacovigilance in 1994 and, in 1996, he was named worldwide head of pharmacovigilance for GlaxoWellcome. After leaving GlaxoWellcome in 1998, he has worked with clinical research organizations (CROs) and has provided consulting services to pharmaceutical companies to advance clinical development programs in respiratory, neurology, infectious disease, and oncology indications.